Apixaban Dosing Recommendations
The recommended dose of apixaban varies by indication: 5 mg twice daily for most patients with atrial fibrillation (reduced to 2.5 mg twice daily if ≥2 dose-reduction criteria are met), 2.5 mg twice daily for postoperative prophylaxis after hip or knee replacement, 10 mg twice daily for 7 days followed by 5 mg twice daily for acute DVT/PE treatment, and 2.5 mg twice daily for extended secondary prevention after completing initial VTE therapy. 1
Atrial Fibrillation Dosing
For stroke prevention in nonvalvular atrial fibrillation, start with 5 mg orally twice daily as the standard dose 1.
Reduce to 2.5 mg twice daily only when patients meet at least TWO of the following criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL 1
This dose-reduction requirement is critical—research shows that 60.8% of patients receiving reduced-dose apixaban in clinical practice did not actually meet labeling criteria for dose reduction 2. The most common error is underdosing based on a single criterion (typically age alone) when two criteria are required 2, 3. Do not reduce the dose based on age, weight, or renal function alone.
Additional dose adjustment applies when combined with strong dual P-glycoprotein and CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): reduce from 5 mg to 2.5 mg twice daily, and avoid use entirely if already on 2.5 mg twice daily 4.
Postoperative VTE Prophylaxis After Hip or Knee Replacement
Use 2.5 mg orally twice daily for all patients regardless of age, weight, or renal function 1.
Timing and duration:
- Start 12-24 hours after surgery
- Continue for 35 days after hip replacement surgery
- Continue for 12 days after knee replacement surgery 1
Acute DVT/PE Treatment
Initial treatment (first 7 days): 10 mg orally twice daily
Continuation therapy (after day 7): 5 mg orally twice daily 1
Continue the 5 mg twice daily dose for at least 6 months for acute VTE treatment 1.
Extended Secondary Prevention of Recurrent DVT/PE
After completing at least 6 months of anticoagulation for DVT or PE, use 2.5 mg orally twice daily for extended secondary prevention 1.
The 2021 CHEST guidelines suggest using reduced-dose apixaban (2.5 mg twice daily) over full-dose apixaban (5 mg twice daily) for extended-phase anticoagulation, though this is a weak recommendation based on very low-certainty evidence 5. Recent 2025 data in cancer-associated VTE demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose for preventing recurrent VTE while significantly reducing clinically relevant bleeding (12.1% vs 15.6%) 6.
Critical Dosing Pitfalls to Avoid
Common prescribing errors include:
- Underdosing atrial fibrillation patients who don't meet the two-criterion threshold (occurs in 16-30% of cases) 2, 7, 3
- Using single criteria (especially age or creatinine alone) to justify dose reduction when two are required
- Failing to account for drug interactions with P-glycoprotein/CYP3A4 inhibitors 4
- Confusing the different dosing regimens across indications
Renal dosing considerations: Unlike dabigatran and rivaroxaban, apixaban does not require dose adjustment for moderate renal impairment (CrCl 30-50 mL/min) in the VTE treatment indication. The dose-reduction criteria for atrial fibrillation (serum creatinine ≥1.5 mg/dL as one of two required criteria) already accounts for renal function 4, 1.
Missed Dose Management
If a dose is missed, take it as soon as possible on the same day and resume the twice-daily schedule. Never double the dose to compensate for a missed dose 1.